SEARCH

SEARCH BY CITATION

References

  • 1
    Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 142632.
  • 2
    McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 148592.
  • 3
    Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395403.
  • 4
    Manns M, McHutchinson J, Gordon S, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C. A randomised trial. Lancet 2001; 358: 95865.
  • 5
    European Association for the Study of the Liver. International Consensus Conference on Hepatitis C. J Hepatol 1999; 30: 95661.
  • 6
    National Institutes of Health. Consensus Development Conference Statement: Management of Hepatitis C, June 2002. http://www.consensus.nih.gov.
  • 7
    Siebert U, Sroczynski G, Rossol S, et al. Cost-effectiveness of pegylated interferon alfa-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. J Hepatol 2002; 36(Suppl. 1): 129(463 Abstract).
  • 8
    Kim WR, Poterucha JJ, Hermans JE, et al. Cost-effectiveness of 6 and 12 months of interferon-α therapy for chronic hepatitis C. Ann Intern Med 1997; 127: 86674.
  • 9
    Buti M, Casado MA, Fosbrook L, Wong JB, Esteban R. Cost-effectiveness of combination therapy for naïve patients with chronic hepatitis C. J Hepatol 2000; 33: 6518.
  • 10
    Bennett WG, Inoue Y, Beck R, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-α2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127: 85565.
  • 11
    Younossi ZM, Singer ME, McHutchinson JG, Shermock KM. Cost-effectiveness of interferon alfa2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999; 30: 131824.
  • 12
    Wong JB, Poynard T, Ling MH, Albrecht JK, Pauker SG. Cost-effectiveness of 24 or 48 weeks of interferon alfa2b alone or with ribavirin as initial treatment of chronic hepatitis C. Am J Gastroenterol 2000; 95: 152430.
  • 13
    Buti M, Casado MA, Fosbrook L, Esteban R. Which is the most cost-effective combination therapy strategy using interferon alfa-2b plus ribavirin for naive patients with chronic hepatitis C? Clin Drug Invest 2002; 22: 319.
  • 14
    Buti M, Casado MA, Fosbrook L, Esteban R. Coste-efectividad de la hepatitis crónica C con interferon alfa. Gastroenterol Hepatol 1998; 21: 1618.
  • 15
    SOIKOS. Base de Datos de Costes Sanitarios. Barcelona: SOIKOS, 1999.
  • 16
    Karlsson G, Johannesson M. The decision rules of cost-effectiveness analysis. Pharmacoeconomics 1996; 9: 11320.
  • 17
    Camma C, Di Marco V, Lo Iacono O, et al. Long-term course of interferon-treated chronic hepatitis C. J Hepatol 1998; 28: 5317.
  • 18
    Lau DTY, Kleiner DE, Ghany MG, Park Y, Schmid P, Hoofnagle JH. 10-year follow-up after interferon-α therapy for chronic hepatitis C. Hepatology 1998; 28: 11217.
  • 19
    Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV-RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127: 87581.
  • 20
    Reichard O, Glaumann H, Frydén A, Norkrans G, Wejstâl Weiland O. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J Hepatol 1999; 30: 7837.
  • 21
    Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. Br Med J 1996; 313: 275283.
  • 22
    Sheperd J, Waugh N, Hewitson P. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review. Health Technol Assess 2000; 4(33).
  • 23
    Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality and costs in the United States. Am J Public Health 2000; 90: 15629.
  • 24
    Weinstein MC. High-priced technology can be good value for money. Ann Intern Med 1999; 130: 8578.
  • 25
    Wong JB, Sonnenberg FA, Salem DN, Pauker SG. Myocardial revascularization for chronic stable angina. Analysis of the role of percutaneous transluminal coronary angioplasty based on data available in 1989. Ann Intern Med 1990; 113: 85271.